Candel Therapeutics (CADL) Non Operating Income: 2020-2023
Historic Non Operating Income for Candel Therapeutics (CADL) over the last 4 years, with Dec 2023 value amounting to -$777,000.
- Candel Therapeutics' Non Operating Income fell 125.75% to -$777,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $452,000, marking a year-over-year decrease of 97.16%. This contributed to the annual value of -$21.8 million for FY2024, which is 4924.34% down from last year.
- According to the latest figures from Q4 2023, Candel Therapeutics' Non Operating Income is -$777,000, which was down 282.39% from $426,000 recorded in Q3 2023.
- Over the past 5 years, Candel Therapeutics' Non Operating Income peaked at $9.3 million during Q4 2021, and registered a low of -$11.8 million during Q2 2021.
- Its 3-year average for Non Operating Income is $499,500, with a median of $309,500 in 2022.
- As far as peak fluctuations go, Candel Therapeutics' Non Operating Income slumped by 4,270.77% in 2021, and later spiked by 4,147.12% in 2022.
- Over the past 4 years, Candel Therapeutics' Non Operating Income (Quarterly) stood at -$4.4 million in 2020, then skyrocketed by 314.47% to $9.3 million in 2021, then tumbled by 67.67% to $3.0 million in 2022, then crashed by 125.75% to -$777,000 in 2023.
- Its last three reported values are -$777,000 in Q4 2023, $426,000 for Q3 2023, and -$35,000 during Q2 2023.